Skip to content

Erasca, Inc. ERAS Total Equity

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$20.07B+15.4%
Eli Lilly logo
Eli LillyLLY
$31.2B+97.9%
Pfizer logo
PfizerPFE
$90.1B-0.3%
Amgen logo
AmgenAMGN
$9.19B+48.1%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$1.5B-27.8%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$391.51M+135%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.25B+1,196%
Enterprise value$4.25B+1,265%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s total equity?
Erasca, Inc. (ERAS) reported total equity of $393.53M in Q1 2026.
How has Erasca, Inc.'s total equity changed year-over-year?
Erasca, Inc.'s total equity decreased by 1.5% year-over-year, from $399.5M to $393.53M.
What is the long-term trend for Erasca, Inc.'s total equity?
Over 5 years (2020 to 2025), Erasca, Inc.'s total equity has grown at a 23.3% compound annual growth rate (CAGR), from -$113.98M to $325.17M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.